【深圳商报讯】（记者陈燕青）要约收购依然是部分公司控股的方式之一。根据Wind统计，年内已有 浩欧博、交大昂立、成大生物、ST新潮等4家公司发布了要约收购相关公告。业内认为，由于要约收购 存在一定的溢价，因此蕴藏部分套利机会。 要约收购是指收购人依照相关法律法规的规定公开向上市公司的全体股东发出收购要约，一般分为全面 要约和部分要约。要约收购约定的收购期限一般不得少于30日，并不得超过60日。各国法律对强制要约 收购触发点的规定各不相同，我国目前的强制要约收购触发点定为30%。 金帝石油此前计划以3.10元/股的价格，要约收购ST新潮20%股份，要约收购期限为4月8日至5月7日。 这样一来，伊泰B股与金帝石油构成竞争性要约，前者的报价比后者提高了近10%。 还有A股公司被港股公司要约收购。浩欧博1月下旬公告，港股中国生物制药通过境内控股子公司双润 正安预定要约收购其1557.05万股，占公司股份总数的25.01%。 从要约收购的目的来看，一是实施行业内横向整合，二是大股东进一步巩固对上市公司的控制权，三是 借此获取控股权。 对此，北方一家券商投行高管对记者表示，通过要约收购，收购方可以快速收购大量股份，从而对 ...

文 | 银行螺丝钉 （转载请注明出处） 一、【直播回放】 港股指数基金的品种也越来越丰富。 常见的港股宽基指数，有恒生、H股、港股中小；策略指数，例如港股红利；行业主题指数，例如港股消费、恒生医疗、港股科技、恒生科技等。 这些指数分别有啥特点？影响港股涨跌走势的原因有哪些？ 如何快速查询港股各个指数的估值数据？ 在昨晚的直播课里，螺丝钉详细介绍了这些问题。 长按识别下面二维码，添加 @课程小助手 微信，回复「 0422 」即可观看直播回放。 （提示：回复后可以耐心等待几秒哦～） 策略指数丰富了我们投资的选项，满足了很多投资者个性化的需求。 第三类是行业指数。 也就是仅覆盖了某个行业的股票，例如消费、医药、金融等。 最常见的行业指数，是11个一级行业。 每个一级行业，其实都是社会不可或缺的一部分，长期也是跟着社会发展的。 第四类是主题指数。 二、【部分直播课内容如下】 1. 港股常见的四类指数 跟A股类似，港股常见的指数，主要也分为四类。 第一类是 宽基 指数。 通常是按照上市公司的市值规模来选股的，会包含各个行业的股票，覆盖范围很"宽"。 第二类是 策略指数 。 通常是在宽基指数的基础上，用了某一种投资策略， ...

对接需求请扫码 每日｜荐读 | 活动： 「2025中国产业资本峰会」圆满落幕，CVC成为投资行业枢纽！ | | --- | | 榜单： 「2025产业投资100强」正式发布 | | 报告： 独角兽的"新双轮驱动"：《2025中国CVC影响力报告》发布 | | 报告： 哪些LP在活跃出资？——《LP全景报告2024》发布 | 据悉，中生引领基金是引领区产业发展基金发起设立的又一支产业基金，目标总规模10亿元，首 关规模5亿元，由浦东创投集团旗下浦东资本担任基金管理人，首关出资人包括浦东创投集团、中 国生物制药、孚腾资本、杭州科百特。基金成立后将聚焦服务生物医药产业，精准高效解决生物医 药产业"融资难、周期长、风险高"痛点，推动生物医药产业向高端化、国际化、集群化方向发展。 按照投资策略，中生引领基金聚焦成长期创新型生物医药企业开展投资，赋能企业在研发、生产、 销售等全流程环节。未来，浦东创投集团与中国生物制药将重点以市场化方式整合优质要素资源， 培育一批具有全球竞争力的领军企业，推动生物医药产业高质量发展，为浦东现代化产业体系建设 注入新动能。 来源：浦东发布 4月22日上午，中生引领（上海）私募投资基金（以下 ...

Core Insights - The establishment of Zhongsheng Leading (Shanghai) Private Equity Fund aims for a total target size of 1 billion yuan, with an initial closing size of 500 million yuan [1] - The fund is managed by Pudong Capital, a subsidiary of Pudong Venture Capital Group, and its initial investors include Shanghai Guotou Futeng Capital, Pudong Venture Capital Group, China National Pharmaceutical Group, and Hangzhou Kebaite [1] - The fund will focus on addressing the challenges of financing difficulties, long cycles, and high risks in the biopharmaceutical industry, promoting the industry's development towards high-end, international, and clustered directions [1]

Group 1 - The Zhongsheng Leading Fund, initiated by Pudong Venture Capital and China National Pharmaceutical Group, aims for a total scale of 1 billion yuan, with an initial closing scale of 500 million yuan [1] - The fund focuses on investing in growth-stage innovative biopharmaceutical companies, supporting them throughout the entire process of research, production, and sales [1] - Pudong New Area plans to continuously build platforms, integrate resources, optimize services, and gather talent to support the high-quality development of the biopharmaceutical industry [1] Group 2 - The biopharmaceutical industry is a core driver of new productive forces in Pudong New Area, which has become one of the most complete and innovative regions for biopharmaceutical industry chains in China [2] - The biopharmaceutical industry scale in Pudong is projected to reach 410 billion yuan by 2024 [2] Group 3 - The biopharmaceutical sector is currently facing a capital winter, with a 9.3% year-on-year decline in medical financing scale expected in 2024 [3] - There is a pressing need for state-owned enterprises to establish biopharmaceutical industry funds to address financing difficulties, long cycles, and high risks in the industry [3] - The Zhongsheng Leading Fund aims to create an innovative model of "state-owned guidance + industry leader empowerment" to align with the development plans of Shanghai and Pudong's biopharmaceutical industry [3]

Group 1 - The Hong Kong pharmaceutical ETF (513700.SH) increased by 3.14%, with major constituents such as Xintai Medical rising by 60%, Meizhong Jiahe by 26%, and Nuocheng Jianhua by 13% [1] - Yuan Da Pharmaceutical announced a milestone breakthrough in its clinical research for the innovative radioactive nuclide-conjugated drug (RDC) GPN02006 for diagnosing hepatocellular carcinoma (HCC), achieving high-quality imaging within 30 minutes of administration [1] - GPN02006 provides strong molecular imaging evidence for personalized treatment plans, addressing the clinical need for rapid diagnosis of HCC and improving early diagnosis rates and monitoring of recurrence and metastasis [1] Group 2 - Guojin Securities believes that innovative drugs in the Hong Kong stock market will be a key investment theme in 2025, driven by AI enabling shorter R&D cycles, reduced costs, and improved efficiency [2] - The recovery of investment and financing activities in the global pharmaceutical industry is beneficial for improving cash flow for innovative drug companies [2] - Anticipation of fiscal stimulus, including the imminent release of the "Class B Directory," may catalyze valuation and sentiment recovery in the sector [2]

Core Viewpoint - The establishment of Zhongsheng Leading (Shanghai) Private Equity Fund aims to support the development of innovative biopharmaceutical enterprises in their growth phase, with a total target size of 1 billion yuan and an initial closing size of 500 million yuan [1] Group 1 - Zhongsheng Leading Fund is initiated by the Leading District Industrial Development Fund [1] - The fund is managed by Pudong Capital, a subsidiary of Pudong Investment Group [1] - Initial investors include Pudong Investment Group, China National Pharmaceutical Group, Foton Capital, and Hangzhou Kebaite [1] Group 2 - The investment strategy focuses on empowering enterprises across the entire process of research and development, production, and sales [1]

Group 1 - The core index, the CESHKB, closed flat with a trading volume of 0.0 billion, reflecting a recent decline of 6.54% over the past month, but an increase of 26.60% over the last three months and a year-to-date rise of 21.09% [1] - The CESHKB index is compiled by China Securities Index Co., Ltd. under the commission of China Securities Trading Service Co., Ltd., aiming to reflect the overall performance of biotechnology companies listed in Hong Kong [1] - The base date for the index is December 12, 2014, with a base point of 2000.0 [1] Group 2 - The top ten holdings of the CESHKB index include: CanSino Biologics (11.12%), Innovent Biologics (10.75%), BeiGene (10.09%), WuXi Biologics (9.6%), China National Pharmaceutical Group (9.38%), Zai Lab (5.61%), 3SBio (5.2%), WuXi AppTec (4.56%), Kelun-Biotech (4.25%), and Genscript Biotech (3.54%) [1] - The index's holdings are entirely composed of companies listed on the Hong Kong Stock Exchange, with the biotechnology sector representing 60.67%, pharmaceutical and biotechnology services at 22.64%, chemical drugs at 13.14%, and medical devices at 3.55% [2]

Core Points - The China-Hong Kong-US Technology Index has shown a decline of 14.62% over the past month, 3.85% over the past three months, and 3.32% year-to-date [1] - The index is composed of high liquidity and high market capitalization technology companies listed in Hong Kong and the US, calculated using an equal-weighted method [1] - The index's top ten holdings include companies such as SMIC (3.61%), BYD (3.23%), and Alibaba (2.55%) [1] Market Composition - The Nasdaq Global Select Market accounts for 40.10% of the index, followed by the Hong Kong Stock Exchange at 36.04% and the New York Stock Exchange at 22.41% [2] - The industry breakdown of the index shows that Information Technology comprises 38.88%, Consumer Discretionary 20.37%, and Healthcare 14.75% [2] Index Adjustment Mechanism - The index samples are adjusted biannually, with changes implemented on the next trading day after the second Friday of June and December [2] - New technology companies that rank in the top five by market capitalization in their respective regions will be quickly included in the index after their eleventh trading day [2]

Core Viewpoint - The AI Fund West China Li De Hong Kong Stock Connect New Opportunities Mixed A (008861) reported a profit of 2.35 million yuan for Q1 2025, with a net asset value growth rate of 15.3% during the period [3][4]. Fund Performance - As of April 18, the fund's unit net value was 0.564 yuan, and it is classified as a flexible allocation fund primarily investing in pharmaceutical and medical stocks [4]. - The fund's performance over various time frames includes: - 3-month net value growth rate: 12.49%, ranking 52 out of 129 comparable funds [4]. - 6-month net value growth rate: -4.20%, ranking 99 out of 129 comparable funds [4]. - 1-year net value growth rate: 18.80%, ranking 19 out of 129 comparable funds [4]. - 3-year net value growth rate: -25.47%, ranking 72 out of 104 comparable funds [4]. Risk Metrics - The fund's Sharpe ratio over the past three years is 0.0659, ranking 36 out of 100 comparable funds [9]. - The maximum drawdown over the past three years is 50.65%, with the largest single-quarter drawdown occurring in Q1 2022 at 28.84% [11]. Investment Strategy - The fund manager indicated that the Hong Kong stock market experienced a recovery driven by domestic technological innovation post-Chinese New Year, leading to a revaluation of technology leaders [4]. - The fund has adjusted its positions, taking profits from technology growth stocks while increasing allocations to cyclical sectors and pharmaceuticals [4]. Fund Holdings - As of Q1 2025, the fund's total assets amounted to 17.16 million yuan [15]. - The top ten holdings include Tencent Holdings, Alibaba-W, Hong Kong Exchanges and Clearing, China Mobile, China Resources Beer, Xiaomi Group-W, Kingdee International, China Biologic Products, BeiGene, and Li Auto-W [17]. Portfolio Allocation - The average stock position over the past three years was 81.35%, compared to the industry average of 86.88% [14]. - The fund reached a peak stock position of 89.48% at the end of Q3 2023, with a low of 72.27% at the end of H1 2023 [14].